131 related articles for article (PubMed ID: 21976530)
1. Palliation and survival after repeated (188)Re-HEDP therapy of hormone-refractory bone metastases of prostate cancer: a retrospective analysis.
Biersack HJ; Palmedo H; Andris A; Rogenhofer S; Knapp FF; Guhlke S; Ezziddin S; Bucerius J; von Mallek D
J Nucl Med; 2011 Nov; 52(11):1721-6. PubMed ID: 21976530
[TBL] [Abstract][Full Text] [Related]
2. Repeated bone-targeted therapy for hormone-refractory prostate carcinoma: tandomized phase II trial with the new, high-energy radiopharmaceutical rhenium-188 hydroxyethylidenediphosphonate.
Palmedo H; Manka-Waluch A; Albers P; Schmidt-Wolf IG; Reinhardt M; Ezziddin S; Joe A; Roedel R; Fimmers R; Knapp FF; Guhlke S; Biersack HJ
J Clin Oncol; 2003 Aug; 21(15):2869-75. PubMed ID: 12885803
[TBL] [Abstract][Full Text] [Related]
3. Palliation and survival after repeated 188Re-HEDP therapy of hormone-refractory bone metastases of prostate cancer: a retrospective analysis.
Orsini F; Guidoccio F; Mazzarri S; Mariani G
J Nucl Med; 2012 Aug; 53(8):1330-1; author reply 1332. PubMed ID: 22717979
[No Abstract] [Full Text] [Related]
4. Re-186(Sn) HEDP for treatment of painful osseous metastases: initial clinical experience in 20 patients with hormone-resistant prostate cancer.
Maxon HR; Schroder LE; Thomas SR; Hertzberg VS; Deutsch EA; Scher HI; Samaratunga RC; Libson KF; Williams CC; Moulton JS
Radiology; 1990 Jul; 176(1):155-9. PubMed ID: 1693784
[TBL] [Abstract][Full Text] [Related]
5. Dosimetry of 188Re-hydroxyethylidene diphosphonate in human prostate cancer skeletal metastases.
Liepe K; Hliscs R; Kropp J; Runge R; Knapp FF; Franke WG
J Nucl Med; 2003 Jun; 44(6):953-60. PubMed ID: 12791825
[TBL] [Abstract][Full Text] [Related]
6. Phase 2 study of a high dose of 186Re-HEDP for bone pain palliation in patients with widespread skeletal metastases.
Pirayesh E; Amoui M; Mirzaee HR; Tabei F; Rakhsha A; Kalantari BA; Shafiei B; Assadi M; Asli IN
J Nucl Med Technol; 2013 Sep; 41(3):192-6. PubMed ID: 23918612
[TBL] [Abstract][Full Text] [Related]
7. [186Re]HEDP in the palliation of painful bone metastases from cancers other than prostate and breast.
Minutoli F; Herberg A; Spadaro P; Restifo Pecorella G; Baldari S; Aricò D; Altavilla G; Baldari S
Q J Nucl Med Mol Imaging; 2006 Dec; 50(4):355-62. PubMed ID: 17043634
[TBL] [Abstract][Full Text] [Related]
8. Palliative treatment of painful disseminated bone metastases with 186Rhenium-HEDP in patients with lung cancer.
Leondi AH; Souvatzoglou MA; Rapti AS; Leontopoulou SA; Papadaki EK; Datseris EI; Anagnostopoulou US; Zerva CJ
Q J Nucl Med Mol Imaging; 2004 Sep; 48(3):211-9. PubMed ID: 15499295
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of 177Lu-EDTMP in bone metastatic pain palliation in breast cancer and hormone refractory prostate cancer: a phase II study.
Yuan J; Liu C; Liu X; Wang Y; Kuai D; Zhang G; Zaknun JJ
Clin Nucl Med; 2013 Feb; 38(2):88-92. PubMed ID: 23334120
[TBL] [Abstract][Full Text] [Related]
10. The PLACORHEN study: a double-blind, placebo-controlled, randomized radionuclide study with (186)Re-etidronate in hormone-resistant prostate cancer patients with painful bone metastases. Placebo Controlled Rhenium Study.
Han SH; de Klerk JM; Tan S; van het Schip AD; Derksen BH; van Dijk A; Kruitwagen CL; Blijham GH; van Rijk PP; Zonnenberg BA
J Nucl Med; 2002 Sep; 43(9):1150-6. PubMed ID: 12215552
[TBL] [Abstract][Full Text] [Related]
11. Treatment of painful bone metastases in prostate and breast cancer patients with the therapeutic radiopharmaceutical rhenium-188-HEDP. Clinical benefit in a real-world study.
Lange R; Overbeek F; de Klerk JM; Pasker-de Jong PC; van den Berk AM; Ter Heine R; Rodenburg CJ; Kooistra A; Hendrikse NH; Bloemendal HJ
Nuklearmedizin; 2016 Sep; 55(5):188-95. PubMed ID: 27443809
[TBL] [Abstract][Full Text] [Related]
12. Serum hemoglobin levels predict response to strontium-89 and rhenium-186-HEDP radionuclide treatment for painful osseous metastases in prostate cancer.
van der Poel HG; Antonini N; Hoefnagel CA; Horenblas S; Valdes Olmos RA
Urol Int; 2006; 77(1):50-6. PubMed ID: 16825816
[TBL] [Abstract][Full Text] [Related]
13. Safety and efficacy of repeated sequential administrations of Re-186(Sn)HEDP as palliative therapy for painful skeletal metastases. Initial case reports of two patients.
Englaro EE; Schroder LE; Thomas SR; Williams CC; Maxon HR
Clin Nucl Med; 1992 Jan; 17(1):41-4. PubMed ID: 1371956
[TBL] [Abstract][Full Text] [Related]
14. A Freeze-Dried Kit for the Preparation of (188)Re-HEDP for Bone Pain Palliation: Preparation and Preliminary Clinical Evaluation.
Mallia MB; Shinto AS; Kameswaran M; Kamaleshwaran KK; Kalarikal R; Aswathy KK; Banerjee S
Cancer Biother Radiopharm; 2016 May; 31(4):139-44. PubMed ID: 27183437
[TBL] [Abstract][Full Text] [Related]
15. The tolerance and therapeutic efficacy of rhenium-188 hydroxyethylidene diphosphonate in advanced cancer patients with painful osseous metastases.
Cheng A; Chen S; Zhang Y; Yin D; Dong M
Cancer Biother Radiopharm; 2011 Apr; 26(2):237-44. PubMed ID: 21539455
[TBL] [Abstract][Full Text] [Related]
16. Effects of low-dose cisplatin on 89Sr therapy for painful bone metastases from prostate cancer: a randomized clinical trial.
Sciuto R; Festa A; Rea S; Pasqualoni R; Bergomi S; Petrilli G; Maini CL
J Nucl Med; 2002 Jan; 43(1):79-86. PubMed ID: 11801708
[TBL] [Abstract][Full Text] [Related]
17. Management of metastatic bone pain with repeated doses of rhenium 186-HEDP in patients under therapy with zoledronic acid: a safe and additively effective practice.
Zafeirakis A; Zissimopoulos A; Baziotis N; Limouris GS
Cancer Biother Radiopharm; 2009 Oct; 24(5):543-50. PubMed ID: 19877884
[TBL] [Abstract][Full Text] [Related]
18. Rhenium-186(Sn)HEDP for treatment of painful osseous metastases: results of a double-blind crossover comparison with placebo.
Maxon HR; Schroder LE; Hertzberg VS; Thomas SR; Englaro EE; Samaratunga R; Smith H; Moulton JS; Williams CC; Ehrhardt GJ
J Nucl Med; 1991 Oct; 32(10):1877-81. PubMed ID: 1717669
[TBL] [Abstract][Full Text] [Related]
19. Safety and efficacy of the specific endothelin-A receptor antagonist ZD4054 in patients with hormone-resistant prostate cancer and bone metastases who were pain free or mildly symptomatic: a double-blind, placebo-controlled, randomised, phase 2 trial.
James ND; Caty A; Borre M; Zonnenberg BA; Beuzeboc P; Morris T; Phung D; Dawson NA
Eur Urol; 2009 May; 55(5):1112-23. PubMed ID: 19042080
[TBL] [Abstract][Full Text] [Related]
20. Palliative analgesic effect of Re-186 HEDP in various cancer patients with bone metastases.
Küçük NO; Ibiş E; Aras G; Baltaci S; Ozalp G; Bedük Y; Canakci N; Soylu A
Ann Nucl Med; 2000 Aug; 14(4):239-45. PubMed ID: 11023023
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]